Longitudinal, disease-level data are used to analyze the impact of pharmaceutical innovation on longevity (mean age at death), hospital utilization, and medical expenditure in Greece during the period 1995 - 2010. The estimates indicate that pharmaceutical innovation increased mean age at death...

We analyze the association that pharmaceutical innovation had with premature mortality from all diseases in Switzerland during the period 1996-2018, and its association with hospital utilization for all diseases in Switzerland during the period 2002-2019. The analysis is performed by...